我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
83
14 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
49
59.0%
尚未招募
14
16.9%
招募中
20
24.1%
暂无批准数据
- Alpha Fusion and Kobe City Medical Center General Hospital have established the world's first company-sponsored supply system for Astatine-211 investigational drugs, overcoming a major global bottleneck in targeted alpha therapy development. - The partnership enables clinical testing of af-001, targeting differentiated thyroid cancer by exploiting At-211's unique property of being taken up by the Sodium-Iodide Symporter for selective cancer cell accumulation. - This multi-site supply chain connects radionuclide production, GMP drug manufacturing, and clinical trial sites, representing a landmark achievement that could transform At-211 from academic research to clinical practice.
